SecBot SecBot
8-K ·Filed Oct 6, 2026

GIPL

Global Innovative Platforms Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed20d 21h ago SEC0001376474-26-000629
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor next 10-Q for any improvement in financial reporting timeliness or quality; the appointment of a fractional CFO with public company experience may signal preparation for more rigorous SEC compliance as the company advances its VetBreath platform.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+5d
GIPL ▲ 0.00% at T+5d
NEUTRAL call 0.00% · α vs SPY +0.98% · entry $0.5000 → $0.5000
Next anchor: T+20d in 7d
Latest observation: T+12 -0.55% FF3 residual α
Entry = T+0 close
Oct 6, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.42%
$0.5000
settled 20d ago
T+5d
0.00%
call 0.00% · α +0.98%
$0.5000
settled 14d ago
T+20d
Pending
in 7d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

Global Innovative Platforms appointed David R. Wells as Fractional CFO via a services agreement with his firm Atlas Bookkeeping, LLC, paying $8,000/month ($96,000 annualized). Andrew Brown stepped down as principal financial/accounting officer but remains CEO. The filing is a routine administrative change for an early-stage company developing a veterinary breath diagnostics platform.

Key Facts

  • David R. Wells appointed Fractional CFO effective October 1, 2026, replacing Andrew Brown as principal financial and accounting officer
  • Services Agreement with Atlas Bookkeeping, LLC (owned by Wells) for $8,000/month ($96,000 annualized)
  • Andrew Brown remains CEO and board member; departure as PFO/PAO not due to any disagreement
  • Company is developing VetBreath Analytics, a non-invasive breath-based diagnostic platform for canine heartworm detection (still in development/validation stage)

Financial Impact

New recurring expense of $96,000 per year for outsourced CFO services; no material financial impact disclosed

operating expenses

Risk Factors

  • Early-stage company with no disclosed revenue and limited operating history
  • Technology still in development/validation stage with no regulatory clearance
  • CFO services provided through a third-party entity with no fixed term agreement

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001376474-26-000629
Document: gipl_ex99z1.htm0001376474-26-000629
Document: 0001376474-26-000629-index-headers.html0001376474-26-000629
Document: 0001376474-26-000629-index.html0001376474-26-000629
Document: 0001376474-26-000629.txt0001376474-26-000629
3 reports for GIPL
Performance horizon
Filters
Rows
Reports for GIPL — sortable, filterable
TypeNow
Oct 6, 2026
20d ago
8-K
NEUTRAL ★ 2/10
$0.5000awaiting T+20—$0.5000 (0.00%)
Jun 15, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$0.5000 $0.4999▼ −0.02%▲ +0.12%$0.5000 (0.00%)
May 20, 2026
22w ago
8-K
NEUTRAL ★ 2/10
$0.5000 $0.5000· 0.00%▼ −0.33%$0.5000 (0.00%)
Showing 3 of 3

US Market Status

Market Open — Closes in 1h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 6, 2026